Gravar-mail: PATH-20. COMPREHENSIVE GENOMIC PROFILING COMPARING PRIMARY CNS LYMPHOMA TO SYSTEMIC DIFFUSE LARGE B CELL LYMPHOMA REVEALS BIOMARKERS INDICATING POTENTIAL BENEFIT FROM IMMUNE CHECKPOINT INHIBITORS